AUTHORS
Yugal Goel, PhD, Donovan Alexander Argueta, PhD2, Carolina Mireles, BS3, Reina Lomeli4, Richard Prince5, Joel Friedman6, Kalpna Gupta, PhD7
AFFILIATIONS
1 Hematology/Oncology Division, Department of Medicine, University of California, Irvine, California, United States
2 Hematology/Oncology Division, Department of Medicine, University of California, Irvine, California, United States
3 Hematology/Oncology Division, Department of Medicine, University of California, Irvine, California, United States
4 Hematology/Oncology Division, Department of Medicine, University of California, Irvine, California, United States
5 Vascarta Inc, Summit, New Jersey, United States
6 Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York, United States, Vascarta Inc, Summit, New Jersey, United States
7 Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, Minnesota, United States, Hematology/Oncology Division, Department of Medicine, University of California, Irvine, California, United States
ABSTRACT
Background: Unpredictable and recurrent acute pain caused by vaso-occlusive crises (VOC) is a debilitating comorbidity of sickle cell disease (SCD). While VOC stems from blood vessel occlusion, the exact central mechanisms translating this into severe acute pain remain poorly understood. Simulating VOC via incitement of hypoxia/reoxygenation (H/R), we examined spinal pro-nociceptive inflammatory, oxidative stress, and neuronal injury pathways.
Methods: We evaluated whether H/R or a hypoxic-sickle microenvironment induces pro-nociceptive neuronal calcium release, pro-inflammatory microglial activity, and nociceptive signaling involving p38 mitogen activated protein kinase (MAPK), STAT3, and ERK1/2. We tested a transdermal curcumin formulation (TDC/VAS-101) to target these pathways. In vitro, HT22 neuronal cells and primary spinal microglia from humanized female HbSS-BERK and HbAA-BERK mice were incubated with tumor necrosis factor alpha (TNF-α, 1 ng/mL) plus hemin (40 µM; T+H), alongside cobalt chloride (CoCl₂; 100 µM) to incite hypoxia. In vivo, female HbSS mice and HbAA control mice underwent two cycles of H/R (8% O₂ for 3 h, 1 h reoxygenation at normoxia), 48 h apart. Mice received topical vehicle or TDC (0.1 mL/day) by gentle abdominal application for 2 weeks prior to and during incitement of H/R. A separate cohort received intrathecal IL-17A neutralizing antibody (0.25 µg/g) 4 h before H/R.
Results: In vitro, T+H+CoCl₂ significantly increased intracellular calcium in HT22 cells compared to vehicle (P<0.001) and T+H alone (P<0.05); this hallmark pro-nociceptive signaling was attenuated by TDC (P<0.01). Primary HbSS microglia showed elevated cell-associated and secreted IL-17A after T+H (P<0.001), which further increased with coadministration of CoCl₂ (P<0.01). TDC significantly reduced both cell-associated and secreted IL-17A (P<0.001 and P<0.01, respectively).
In vivo, vehicle-treated HbSS mice exposed to H/R exhibited increased plasma IL-17A and spinal Hypoxyprobe™ immunoreactivity indicative of hypoxia (P<0.05 and P<0.01 vs. normoxia), both of which were attenuated by TDC. Vehicle-treated HbSS mice after H/R also showed elevated spinal malondialdehyde (MDA; P<0.0001) and plasma serum amyloid P (SAP; P<0.0001) suggestive of oxidative stress and global inflammation, respectively, compared to HbAA controls; TDC treatment significantly reduced H/R-induced increases in MDA and SAP (P<0.01). In the spinal dorsal horn, H/R increased phospho-p38 MAPK-positive nuclei (P<0.0001) and IBA1-positive activated microglia (P<0.01) versus normoxic HbSS mice, which were attenuated by TDC (P<0.0001 and P<0.001, respectively). Spinal phospho-STAT3 and phospho-ERK1/2 were similarly elevated in vehicle-treated HbSS mice after H/R versus HbAA controls (P<0.01) and were ameliorated by TDC (P<0.05). Intrathecal IL-17A antibody significantly reduced H/R-induced spinal ERK1/2 phosphorylation compared to vehicle-treated H/R HbSS mice (P<0.01), indicating a critical role of IL-17A in the initiation and maintenance of central pro-nociceptive pathways.
Conclusions: H/R promotes acute sickle pain through a complex cascade of neuronal calcium dysregulation, microglial IL-17A production, spinal hypoxia, oxidative stress, and activation of p38 MAPK, STAT3, and ERK1/2 signaling. IL-17A drives spinal ERK1/2 activation, contributing to pain behaviors. Because TDC prevents these central neuroinflammatory mechanisms, targets peripheral axonal injury, and prevents erythrocyte sickling, early-life treatment with TDC represents a promising strategy to prevent acute pain episodes and accompanying cellular injury in SCD.
DISCLOSURES
Yugal Goel, PhD: No relevant conflicts of interest to declare.